Charles River Laboratories (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 117,947 | 160,023 | 155,927 | 109,685 | 68,905 |
| Receivables | 270,068 | 257,991 | 220,630 | 203,001 | 184,810 |
| Inventories | 93,735 | 89,043 | 89,396 | 88,470 | 92,969 |
| Other current assets | 47,286 | 45,297 | 86,597 | 84,096 | 79,159 |
| TOTAL | $559,234 | $579,254 | $552,550 | $485,252 | $425,843 |
| Non-Current Assets | |||||
| PPE Net | 677,959 | 676,797 | 676,182 | 717,020 | 738,030 |
| Intangibles | 506,259 | 338,551 | 315,238 | 293,531 | 290,998 |
| Other Non-Current Assets | 325,045 | 275,976 | 88,786 | 90,541 | 103,449 |
| TOTAL | $1,509,263 | $1,291,324 | $1,080,206 | $1,101,092 | $1,132,477 |
| Total Assets | $2,068,497 | $1,870,578 | $1,632,756 | $1,586,344 | $1,558,320 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 17,033 | 31,904 | 21,437 | 139,384 | 14,758 |
| Accounts payable and accrued liabilities | 36,675 | 33,815 | 31,770 | 31,218 | 34,332 |
| Accrued Expenses | 162,326 | 138,949 | 115,173 | 92,159 | 95,979 |
| Other current liabilities | 12,544 | 9,595 | 22,546 | 21,262 | 14,033 |
| TOTAL | $311,761 | $294,686 | $247,034 | $342,247 | $216,797 |
| Non-Current Liabilities | |||||
| Long Term Debt | 845,997 | 740,557 | 642,352 | 527,136 | 703,187 |
| Deferred Revenues | 81,343 | 78,124 | 54,177 | 56,422 | 56,530 |
| Other Non-Current Liabilities | 123,186 | 134,821 | 97,970 | 113,190 | 110,562 |
| TOTAL | $1,019,180 | $899,965 | $741,645 | $640,897 | $814,160 |
| Total Liabilities | $1,330,941 | $1,194,651 | $988,679 | $983,144 | $1,030,957 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 46,718 | 47,326 | 47,659 | 48,182 | 48,887 |
| Common Shares | 855 | 845 | 825 | 796 | 785 |
| Retained earnings | 10,538 | -138,775 | -265,473 | -368,301 | -465,596 |
| Other shareholders' equity | -130,797 | -70,783 | 8,570 | 9,389 | 6,253 |
| TOTAL | $737,556 | $675,927 | $644,077 | $603,200 | $527,363 |
| Total Liabilities And Equity | $2,068,497 | $1,870,578 | $1,632,756 | $1,586,344 | $1,558,320 |